Please ensure Javascript is enabled for purposes of website accessibility
ホーム > 製品 > 抗体 > バイオシミラー

Anti-Human IL-5 Reference Antibody (Reslizumab, RUO) (HY218016)

Anti-Human IL-5 Reference Antibody (Reslizumab, RUO)
Anti-Human IL-5 Reference Antibody (Reslizumab, RUO)
Anti-Human IL-5 Reference Antibody (Reslizumab, RUO)
Anti-Human IL-5 Reference Antibody (Reslizumab, RUO)
価格(USD):
スペック:
  • 100ug
  • 1mg
  • 5mg
  • 10mg
  • 25mg
  • 50mg
  • 100mg
数量:
お問い合わせ
  • 概要

  • イメージ

  • 参考文献

  • データシート

  • SDS

概要
カタログ番号HY218016
説明
Reslizumab (HY218016) is a research-grade recombinant antibody targeting IL5. Produced in mammalian cells with native-like glycosylation.
Highlights
  • ●Research Grade — For PK/PD studies, assay development, and ADA research.
  • ●Native Glycosylation — Mammalian expression ensures native-like patterns.
種反応性Human
アプリケーションELISA, Bioactivity: FACS, Functional assay, Research in vivo
宿主種Human
クローン性Monoclonal
アイソタイプIgG4-nd
発現システム Mammalian cells
ターゲット IL5, B-cell differentiation factor I, IL-5, T-cell replacing factor, TRF, Eosinophil differentiation factor, Interleukin-5
エンドトキシンレベル < 10 EU/mg
純度 >95% purity as determined by SDS-PAGE.
精製 Protein A/G purified from cell culture supernatant.
アクセッション番号 P05113
形態 Liquid
保存バッファー 0.01M PBS pH 7.4

データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。

安定性と保存 Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
別名CDP-835, JES1-39D10, SCH55700, 241473-69-8
背景

Interleukin-5 (IL5) is a ~15 kDa protein. Homodimeric cytokine expressed predominantly by T-lymphocytes and NK cells that plays an important role in the survival, differentiation, and chemotaxis of eosinophils. Also acts on activated and resting B-cells to induce immunoglobulin production, growth, and differentiation. Mechanistically, exerts its biological effects through a receptor composed of IL5RA subunit and the cytokine receptor common subunit beta/CSF2RB. Binding to the receptor leads to activation of various kinases including LYN, SYK and JAK2 and thereby propagates signals through the RAS-MAPK and JAK-STAT5 pathways respectively. IL5 is the therapeutic target of mepolizumab (Nucala).

1. Clutterbuck, EJ. et al. (1989) Blood 73, 1504-12. PMID: 2653458
2. Ochiai, K. et al. (1997) Clinical and experimental immunology 107, 198-204. PMID: 9010276
3. Tavernier, J. et al. (1992) Proceedings of the National Academy of Sciences of the United States of America 89, 7041-5. PMID: 1495999
4. Kusano, S. et al. (2012) Protein science : a publication of the Protein Society 21, 850-64. PMID: 22528658
5. Alam, R. et al. (1995) International archives of allergy and immunology 107, 226-7. PMID: 7613138
注意事項 For research use only. Not suitable for clinical or therapeutic use.
Isotype Control Human IgG4 (S228P) Recombinant Isotype Control Antibody (13R4) (HP298207)
Human IgG4 (S228P & L235E) Recombinant Isotype Control Antibody (HyHEL-10) (HP614107)
Human IgG4 (S228P) Recombinant Isotype Control Antibody (SAA0184) (HP298107)
イメージ
  • Anti-Human IL-5 Reference Antibody (Reslizumab, RUO)

    Bioactivity

    SEC-HPLC detection for Research Grade Reslizumab.

  • Anti-Human IL-5 Reference Antibody (Reslizumab, RUO)

    SDS-PAGE

    SDS-PAGE for Research Grade Reslizumab.

参考文献
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
レコメンデーション

お問い合わせ カスタムクォート、大量リクエストおよびその他の問題については

メール: [email protected]

ディストリビューターリスト